Sibylla Biotech

ProtOS

This company develops artificial intelligence models to design de-novo proteins for the degradation of undruggable targets for the pharmaceutical and medical biotechnology industries.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

Enodia

This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.

Plexium

This company develops targeted protein degradation therapeutics and discovery platforms for patients with cancer and neurodegenerative diseases.

Kymera Therapeutics

This biotechnology company develops small molecule medicines that degrade disease-causing proteins for patients with cancer and immune-inflammatory diseases.

Celeris Therapeutics

The company develops artificial intelligence software to design and discover protein degrader drugs for pharmaceutical and biotechnology organisations.

Amphista Therapeutics

This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.

Arvinas

This biopharmaceutical company develops protein degradation therapies to treat patients with cancer and neurodegenerative diseases.